Quince Therapeutics, Inc. - 8-K Filing
Quince Therapeutics announced Phase 2a data showing LAM-001, an inhaled rapamycin formulation acquired from Orphai Therapeutics, improved key measures like six-minute walk distance (6MWD) by 67.4 meters and reduced pulmonary vascular resistance (PVR) by 33.9% in PH-ILD patients over 24 weeks. The Phase 2b trial is set to begin mid-2026 with data expected Q1 2028.
Tickers: $QNCX